

Diagnostica Vertrieb GmbH, Oehleckerring 11-13

22419 Hamburg, Germany

Telephone: +49 (0)89 3799666-6 | **Fax:** +49 (0)89 3799666-99

E-Mail: info@biozol.de

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

XIB4035, CAS [[10023-54-8]] FBM-10-1486

| Article Name | XIB4035, CAS [[10023-54-8]] |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Biozol Catalog Number | FBM-10-1486 |
| Supplier Catalog Number | 10-1486 |
| Alternative Catalog Number | FBM-10-1486-5MG,FBM-10-1486-25MG |
| Manufacturer | Focus Biomolecules |
| Category | Biochemikalien |
| Product Description | GFRalpha1 agonist |
| Molecular Weight | 750.45 |
| Purity | 98% by TLC, NMR (Conforms) |
| Form | Light brown solid |
| CAS Number | [10023-54-8] |
| Formula | C26H31Cl2N3 3(H3PO4) |
| Application Notes | A novel small molecule thought to be an agonist at the glial cell line-derived neurotrophic factor (GDNF) family receptor alpha-1 GFRalpha-1. It inhibits radiolabeled GDNF binding in Neuro-2A cells in a concentration dependent manner IC50=10.4 μM . Like GDNF, it induced Ret autophosphorylation and promoted neurite outgrowth in Neuro-2A cells1. Recent studies indicate that it enhances GFRalpha family receptor signaling in conjunction with ligand stimulation. Effective treatment for small-fiber neuropathy in mouse models of the disease.2,3 GDNF agonists may be a new class of Parkinsons disease therapeutics.4 |